Business Context and Reporting Period
This Form 8-K Current Report from Revelation Biosciences, Inc. (REVB) covers the event date of January 28, 2025. The filing details the implementation of a reverse stock split following a special meeting of stockholders held on January 17, 2025, where shareholders authorized the Board of Directors to determine a split ratio between 1-for-2 and 1-for-50.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed relates to the company's capital structure post-split:
- Post-Split Share Count: Approximately 522,281 shares of common stock were issued and outstanding immediately following the split.
- Split Ratio: 1-for-16 reverse stock split.
- Trading Symbol: REVB (unchanged).
- New CUSIP: 76135L606.
Material Changes Versus Prior Period
The material change reported is the reduction in the number of outstanding shares and the corresponding adjustment to equity instruments:
- Share Conversion: Every 16 pre-split shares were automatically converted into 1 post-split share.
- Fractional Shares: No fractional shares were issued; entitlements were rounded down to the nearest whole share.
- Equity Awards and Warrants: Proportionate adjustments were made to outstanding equity awards and warrants regarding share counts and exercise prices.
- Special Warrant Provisions: Class D and Class G Common Stock Warrants contain price reset features. Their exercise prices (and share counts for Class G) will adjust based on the Volume Weighted Average Price (VWAP) of the common stock in the days following the split.
- Equity Incentive Plans: The number of shares available for issuance under equity incentive plans was proportionately reduced.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the mechanics of the stock split. The primary contingency noted is the rounding down of fractional shares, which results in a loss of value for shareholders holding share counts not evenly divisible by 16.
Investor Verification Checklist
- Verify the exact number of shares held post-split, noting that fractional shares were rounded down.
- Confirm the adjusted exercise price and share count for any held Class D or Class G warrants, as these depend on future VWAP calculations.
- Check the new CUSIP number (76135L606) for trading and settlement purposes.
- Review the definitive proxy statement filed on December 16, 2024, for additional details on the authorization process.